BioPharmCatalyst Introduces Enhanced Suite of Tools for Biotech Investment Community
SAN DIEGO, May 18, 2023 /PRNewswire-PRWeb/ -- BioPharmCatalyst (BPC), a division of Scientist.com, announced today that it has expanded the suite of digital tools it provides biotech investors and other life science professionals. The company's new Elite plan gives users access to BPC's core services and a wide range of new features, including data on historical probabilities of clinical trial success, insider trading activities, mergers and acquisitions as well as a detailed biotech conference calendar. BPC now also provides data and analytics on private biotech companies not yet publicly traded. Larger users such as venture capitalists, growth equity investors and private equity investors can access most of this data through BPC's new Application Programming Interface (API), allowing seamless integration of BPC's rich data into their existing workflows.
- SAN DIEGO, May 18, 2023 /PRNewswire-PRWeb/ -- BioPharmCatalyst (BPC), a division of Scientist.com, announced today that it has expanded the suite of digital tools it provides biotech investors and other life science professionals.
- BPC now also provides data and analytics on private biotech companies not yet publicly traded.
- "Whether you are an institutional investor, a day trader looking to diversify your portfolio or a healthcare professional keeping tabs on the industry, our advanced biotech investing tools and resources will deliver significant value."
- BPC provides indispensable tools to anyone interested in investing in the biotech industry.